course of action in case of announcement, page-9

easysell,

I personally do not think we will hear anything of substance from the company for at least a few months

Surges has already given a great summary but I'll answer your question with another perspective.

First a quick revision of our sp and corresponding Anns for this same period last year before we became de-risked imo.

18/1, 3.3 - 3.3
19/1, 3.4 - 3.8 ~ 2.47pm: ASX Speeding Ticket
20/1, 4.0 - 4.3
21/1, 4.1 - 4.3
22/1, 4.0 - 5.2 ~ 5.20pm: ASX Speeding Ticket
25/1, 5.0 - 5.6
27/1, 5.8 - 5.3
28/1, 5.6 - 3.6 ~ 2.01pm: 3M MTA 60 Day Extension
29/1, 3.3 - 3.1
01/2, 3.0 - 2.9
02/2, 3.0 - 3.1
03/2, 3.2 - 3.4
04/2, 3.4 - 3.4
05/2, 3.2 - 3.2
08/2, 3.3 - 4.4 ~ 11.49am: Statement of Intent from Major Int'l FMCG
09/2, 4.2 - 4.3
10/2, 4.5 - 4.2
11/2, 4.1 - 4.1
12/2, 4.4 - 4.6
15/2, 4.7 - 4.5
16/2, 4.6 - 4.5
17/2, 4.7 - 4.3
18/2, 4.2 - 5.7 ~ 2.40pm: GSK enters into further agreement with OBJ

Since this period last year we have now been presented with much more positive news and imho imminent deals in the making so let me offer a quick comparism of variables imo:

1,123,270,308 shares x 2.7c = $30,328,298

"As only one example, OBJ is working with one of the world's largest pharmaceutical companies in consumer acceptance testing for a patch version of an existing multi-billion dollar product currently sold internationally."

So as an example, licencing and milestone pymts aside, lets assume this existing multi-billion dollar product is only worth say $2 billion p/a to the Pharma giant:

$2,000,000,000 @ 5% royalty pymts to obj = $100,000,000

$100,000,000
+$30,328,298
=$130,328,298
/1,123,270,308

= 8.6c

This speculative sp assumption is based on one license deal only.

However since February 18/2010:

Our MTA with 3M the program of work is now complete and the other party to agreement has reconfirmed its interest... = very successful results and also suggesting a third party collaboration

Our Stmt of Intent with the Major FMCG Company we've since been informed the development of this product is progessing rapidly after the study testing both our DP & eM-patch technologies in a fully formulated patch format achieved up to a 10-fold increase in drug delivery over the existing commercial product with significant international sales.

Since GSK's February announcement they have advised they are proceeding with a FIM development program in a major key sector of consumer healthcare after reporting statistically significant levels of enhancement in testing Since October last year they have progressed discussions regarding a technology integration program and in vivo human efficacy testing to quantify the business opportunity"

+ September 28 - Strategic Alliance with another Global FMCG Company to establish a program for the evaluations across multiple product categories.
If successful, OBJ will grant a license for each product within the field and receive royalties for a period of 5 years or life of patent, whichever is longer.

The majority of OBJs potential partners, including the announced relationships with GSK, 3M and FMCG companies, have widely diversified product portfolios across multiple product categories and sectors.

This statement from the company quantifies my opinion that there may indeed be other partners already conducting development programs with obj tied up in confidentiality agreements before anything of material value will be announced.

Will we recieve the first of some very positive news within the next month?

Imho: Absolutely